Governor Ned Lamont has signed legislation expanding the state’s psychedelic-assisted therapy pilot program, allowing more adults to participate in research involving therapies that use psilocybin and MDMA under medical supervision. The move is designed to prepare Connecticut for the possibility that federal regulators may approve these treatments in the coming years.
The state’s program originally focused on veterans, retired first responders, and healthcare workers. Under the new law, eligibility expands to adults 18 and older who meet clinical criteria established by researchers overseeing the program. The legislation also removes a provision that would have ended the pilot if federal approval occurs, allowing the program to continue gathering data and developing treatment infrastructure.
Supporters say Connecticut is positioning itself to responsibly integrate emerging therapies that have shown promise for conditions such as PTSD, treatment-resistant depression, and other mental health challenges. While these treatments are not yet broadly approved by the FDA, state leaders want to ensure that systems, training, and safeguards are in place if federal approval arrives.
Whether you’re supportive or skeptical, one thing is clear: the conversation around psychedelic medicine is moving from the fringe toward the mainstream.
Dabbin-Dad Newsroom
